| Dr Chris Boseovski, MD | |
|
5212 Piedmont Dr, Santa Rosa, CA 95409-2846 | |
| (707) 494-2802 | |
| Not Available |
| Full Name | Dr Chris Boseovski |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Location | 5212 Piedmont Dr, Santa Rosa, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508940107 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 122300000X | Dentist | 56189 (California) | Secondary |
| 208D00000X | General Practice | 0101276912 (Virginia) | Primary |
| Entity Name | Chris Boseovski Md Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821785403 PECOS PAC ID: 3375909310 Enrollment ID: O20230518000298 |
News Archive
There's no question that as body weight increases, so too does blood pressure. Now, in a study of mice, Johns Hopkins researchers have revealed exactly which molecules are likely responsible for the link between obesity and blood pressure.
After screening more than 2,300 drugs for their ability to halt the growth of breast cancer cells, Johns Hopkins researchers have discovered that the anti-HIV drug nelfinavir slows the progress of HER2-positive tumor cells, even if they are resistant to other breast cancer drugs.
SAS announced today that Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. pharmaceutical company, has selected SAS Solutions OnDemand: Drug Development as a technology platform for clinical development. With SAS OnDemand, DSPA will have a globally accessible, fully regulatory compliant repository for all of its clinical data.
Cells infected by the deadly Ebola virus may release viral proteins such as VP40 packaged in exosomes, which, as new research indicates, can affect immune cells throughout the body impairing their ability to combat the infection and to seek out and destroy hidden virus.
Intellect Neurosciences, Inc. a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has locked the database of the Company's Phase 1b clinical trial for its lead Alzheimer's candidate, OXIGON™ (OX1).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Chris Boseovski, MD 5212 Piedmont Dr, Santa Rosa, CA 95409-2846 Ph: (707) 494-2802 | Dr Chris Boseovski, MD 5212 Piedmont Dr, Santa Rosa, CA 95409-2846 Ph: (707) 494-2802 |
News Archive
There's no question that as body weight increases, so too does blood pressure. Now, in a study of mice, Johns Hopkins researchers have revealed exactly which molecules are likely responsible for the link between obesity and blood pressure.
After screening more than 2,300 drugs for their ability to halt the growth of breast cancer cells, Johns Hopkins researchers have discovered that the anti-HIV drug nelfinavir slows the progress of HER2-positive tumor cells, even if they are resistant to other breast cancer drugs.
SAS announced today that Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. pharmaceutical company, has selected SAS Solutions OnDemand: Drug Development as a technology platform for clinical development. With SAS OnDemand, DSPA will have a globally accessible, fully regulatory compliant repository for all of its clinical data.
Cells infected by the deadly Ebola virus may release viral proteins such as VP40 packaged in exosomes, which, as new research indicates, can affect immune cells throughout the body impairing their ability to combat the infection and to seek out and destroy hidden virus.
Intellect Neurosciences, Inc. a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has locked the database of the Company's Phase 1b clinical trial for its lead Alzheimer's candidate, OXIGON™ (OX1).
› Verified 8 days ago